INREMDY
Live / Applied — First extension granted (statement of use) (as of 15 Dec 2025)
What this means for you
Not registered yet, but its 07 May 2024 filing date beats anything filed after it. If it registers, the owner can stop confusingly similar uses in the classes it covers.
Record
- Serial number
- 98537246
- Mark type
- Stylized text
- Filed
- 07 May 2024
- Published for opposition
- 22 Apr 2025
- Attorney of record
- Danielle Rivera
Goods and services
- Class 005 — Pharmaceuticals: Human pharmaceutical preparations for the prevention and treatment of viral diseases, auto-immune and inflammatory diseases, alloimmune diseases, cardiovascular and pulmonary diseases, central nervous system diseases, peripheral neurological system diseases, pain, dermatologic diseases, gastro-intestinal diseases, infectious-related diseases, metabolic diseases, oncologic diseases, ophthalmic diseases, respiratory diseases, hematological diseases, urological diseases, maternal fetal disorders, digital ulcers
Owner
- Johnson & Johnson, New Brunswick, NJ, US
- Johnson & Johnson, New Brunswick, NJ, US
Prosecution history
- 16 Dec 2025 — NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
- 15 Dec 2025 — SOU EXTENSION 1 GRANTED
- 15 Dec 2025 — SOU EXTENSION 1 FILED
- 15 Dec 2025 — SOU TEAS EXTENSION RECEIVED
- 17 Jun 2025 — NOA E-MAILED - SOU REQUIRED FROM APPLICANT
- 22 Apr 2025 — OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
- 22 Apr 2025 — PUBLISHED FOR OPPOSITION
- 16 Apr 2025 — NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
- 24 Mar 2025 — APPROVED FOR PUB - PRINCIPAL REGISTER
- 24 Mar 2025 — EXAMINER'S AMENDMENT ENTERED
- 24 Mar 2025 — NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED
- 24 Mar 2025 — EXAMINERS AMENDMENT E-MAILED
- 24 Mar 2025 — EXAMINERS AMENDMENT -WRITTEN
- 17 Mar 2025 — TEAS/EMAIL CORRESPONDENCE ENTERED
- 17 Mar 2025 — CORRESPONDENCE RECEIVED IN LAW OFFICE